ARTERIAL HYPERTENSION AND MEDICAL SUPPORT OF PATIENTS WITH PERMANENT PACEMAKERS
Анотація
The review is devoted to clinical problems of arterial hypertension (AH) in patients with implanted pacemakers (EKS) and cardiac resynchronization therapy (CRT). Indications for pacemaker implantation and CRT are considered, especially the purpose and effectiveness of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARA, sartans), beta-blockers (BAB), diuretics, calcium channel blockers. We prove that the CRT and cardiac pacing and do not cancel, bur modify drug therapy of AH. The analysis of the literature has shown that despite the fact that cardiac pacing and CRT in the presence of possible solutions to the problem of arrhythmias and HF it does not cancel, but modifies the medical support of patients, which has been little studied. As for the features of the medical control of AH in patients with a pacemaker and CRT, this question has not been practically studied, and the existing proposals do not go beyond existing recommendations for treatment in the general population. The foregoing determines the exceptional relevance of studying the problem of drug control of AH in these patients.
Завантаження
Посилання
Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study / [C. Linde, A. Curtis, G. Fonarow et all.]. // Int J Cardiol. – 2016. – p. 55–349.
Acute and chronic high-frequency properties of cardiac pacing and defibrillation leads / D.Tomasic, B. Ferek-Petric, S. Brusich, A. Accardo. // Med Biol Eng Comput. – 2012. – p. 37–827.
Falk V. Cardiac pacing - Will the future be exclusively leadless? / V. Falk, C. Starck. // Expert Rev Med Devices. – 2016. – p. 2–421.
David M. Cardiac pacing and device therapy / M. David, R. Archana. // Springer. – 2012. – p. 1–43.
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy / [M. Brignole, A. Auricchio, B. Gonzalo et al.] // European Heart Journal. – 2013. – p. 2281–2329.
Cardiac Resynchronization Therapy: An Overview on Guidelines. / G.Boriani, M. Nesti, M. Ziacchi, L. Padeletti. // Card Electrophysiol Clin. – 2015. – p. 93–673.
Efficacy of biventricular pacing on preventing heart failure in patients with high degree atrioventricular block (BIVPACE-AVB Trial). / [X. Zhang, Q. Shan, Y. Su et al.] // Zhonghua Xin Xue Guan Bing Za Zhi. – 2016. – p. 7–331.
A review on advanced atrioventricular block in young or middle-aged adults / [S. Barra, R. Providência, L. Paiva et al.] // Pacing Clin Electrophysiol. – 2012. – № 35. – p. 405–1395.
The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study / [M. Gold, C. Daubert, W. Abraham et.al.] // Heart Rhythm. – 2015. – № 12. – p. 30–524.
Relationship between pre-implant ejection fraction and outcome after cardiac resynchronization therapy in symptomatic patients. / [A. Schuchert, C. Muto, T. Maounis et al.] // Acta Cardiol. – 2014. – № 69. – p. 32–424.
Change of quality of life and NYHA class in patients with advanced heart failure and permanent atrial fibrillation after 12-months period from upgrade of pacing system / B.Małecka, A. Zabek, J. Lelakowski, J. Małecki. // Pol Merkur Lekarski. – 2012. – № 32. – p. 9–13.
Key recommendations of the clinical guidelines of arterial hypertension in primary care / [A. Valenzuela-Flores, F. Solórzano-Santos, A. Valenzuela-Flores et al.] // Rev Med Inst Mex Seguro Soc. – 2016. – p. 60–249.
Stefanadis C. Management of arterial hypertension: from no treatment to renal denervation / C. Stefanadis // Hellenic J Cardiol. – 2015. – p. 8–277.
Lazebnik L.B. arterial hypertension and comorbidity / L.B Lazebnik, I.A Komisarenko // V mire lekarstv. – 2000. – № 3. – p. 20–26.
Recommendations of Ukrainian Association of Cardiology on prevention and treatment of hypertension. Guide to the National Programme for prevention and treatment of hypertension, 2008. – 80 p.
ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)/ / [M. Giuseppe, F. Robert, N. Krzysztof et al.] // European Heart Journal. – 2013. – № 34. – p. 2163–2168.
Prevalence, treatment and control of hypertension in La Réunion: the RÉDIA population-based cohort study. / [M. Cournot, V. Lenclume, N. Le Moullec et.al.] // Blood Press. – 2016. – p. 1–9.
Awareness, treatment, and control of hypertension in Austria: a multicentre cross-sectional study / [M. Rohla, M. Tscharre, K. Huber et al.] // J Hypertens. – 2016. – p. 11–67.
Achievement of cardiometabolic targets in aware hypertensive patients in Spain: a nationwide population-based study / [J. Banegas, A. Graciani, J. de la Cruz-Troca et al.] // Hypertension. – 2012. – № 60. – p. 898–905.
Hypertension related knowledge and behaviour associated with awareness, treatment and control of hypertension in a rural hypertensive population: a community based, cross-sectional survey / [S. Li, F. Zhou, Y. Lu та et al.] // Blood Press. – 2016. – p. 1–7.
Low-level exposure to lead, blood pressure, and hypertension in a population-based cohort. / [A. Gambelunghe, G. Sallsten, Y. Borné et al.] // Environ Res. – 2016. – p. 157–163.
Blood pressure reverse dipping may associate with stable coronary artery disease in patients with essential hypertension: a cross-sectional study. / [B. Yan, L. Sun, Y. Gao et al.] // Sci Rep. – 2016. – p. 25410–25550.
Thomopoulos C. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. / C. Thomopoulos, A. Zanchetti, G. Parati. // J Hypertens. – 2016. – p. 22–613.
Cardiac memory in cardiac resynchronization therapy: A vectorcardiographic comparison of biventricular and left ventricular pacing. / [L. Perrotta, G. Ricciardi, P. Pieragnoli et al.] // J Electrocardiol. – 2015. – № 48(4). – p. 7–571.
Kolterer B Improved quality of life after treatment of prolonged asystole during breath holding spells with a cardiac pacemaker / [B. Kolterer, R. Gebauer, J. Janousek et al.] // Medicine (Baltimore). – 2016. – № 95. – p. 95–320.
Quality of life in cardiac resynchronization recipients: association with response and impact on outcome / [R. Lenarczyk, E. Jędrzejczyk-Patej, M. Mazurek et al.] // Pacing Clin Electrophysiol. – 2015. – № 38(1). – p. 8–17.
Evaluation of patients' quality of life aspects after cardiac pacemaker implantation / R. Barros, S. Carvalho, M. Silva, J. Borges. // Rev Bras Cir Cardiovasc. – 2014. – № 29(1). – p. 37–44.
Dynamics of BP in patients with arterial hypertension after the cardiac pacingr/T. E. Naples, and M. Davidovich, S. A. Skopeckaâ, Y. Bondar. Annex I to the magazine «Cardiovascular therapy and prophylaxis». – 2011. – 10 (6). – P. 218.
Cardiac resynchronization therapy (CRT) with right ventricular sense triggered left ventricular pacing benefits for the hemodynamics compared with standard CRT for chronic congestive heart failure: A cross-over study. / [L. Pu, Y. Wang, L. Zhao et al.] // Cardiol J. – 2015. – № 22(1). – p. 6–80.
Leadless Cardiac Pacemakers: Back to the Future. / M.Miller, P. Neuzil, S. Dukkipati, V. Reddy // J Am Coll Cardiol. – 2015. – № 66(10). – p. 89–1179.
The Pacemaker and Implantable Cardioverter-Defibrillator Registry of the Italian Association of Arrhythmology and Cardiac Pacing--Annual report 2014 / [A. Proclemer, M. Zecchin, A. D'Onofrio et al.] // G Ital Cardiol (Rome). – 2016. – № 17(2). – p. 95–107.
Syvolap V.V. Features of intracardiac hemodynamics and diastolic function in patients with coronary heart disease with complete atrioventricular blockade before and after pacing in VVI mode/ V.V. Syvolap. Ukrainian medical chasopis. – 2003. – № 1. – p. 75–78
33. Effects of AV-delay optimization on hemodynamic parameters in patients with VDD pacemakers. / [K. Krychtiuk, M. Nürnberg, R. Volker et al.] // Wien Klin Wochenschr. – 2014. – № 126. – p. 7–270
Ponomarenko V. B. Results of treatment in patients with atrioventricular blockade (retrospective data analysis)/V. B. Ponomarenko. Vestnik Arrhythmology. – 2001. – № 22. – P. 5–12
Electrophysiological Disorders of the Heart / [S. Sanjeev, J. Camm, P. Boyden et al.]. – Philadelphia, 2005. – 1220 p. – (Churchill Livingstone).
Zipes D. Cardiac Electrophysiology From Cell to Bedside Part 2 / D. Zipes, J. Jalife., 2014. – 662 p. – (Elsevier).
First-degree atrioventricular block is associated with advanced atrioventricular block, atrial fibrillation and left ventricular dysfunction in patients with hypertension / [J. Uhm, J. Shim, J. Wi et al.]. // J Hypertens. – 2014. – № 32. – p. 20–1115.
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch blockoccurring during transcatheter aortic valve implantation / [F. Egger, M. Nürnberg, M. Rohla et al.]. // Heart Rhythm. – 2014. – № 11. – p. 82–2176.
Outcome in young patients with isolated complete atrioventricular block and permanent pacemaker treatment: A nationwide study of 127 patients / [H. Eliasson, S. Sonesson, S. Salomonsson et al.]. // Heart Rhythm. – 2015. – № 12. – p. 84–2278.
Prevalence of E/A wave fusion and A wave truncation in DDD pacemaker patients with complete AV block under nominal AV intervals / W.Poller, H. Dreger, M. Schwerg, С. Melzer. // PLoS One. – 2015. – № 10(2). – p. 2–45.
Biventricular pacing for atrioventricular block and systolic dysfunction / [A. Curtis, S. Worley, P. Adamson et al.]. // N Engl J Med. – 2013. – № 368(17). – p. 93–1585.
Association of sick sinus syndrome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities study and Cardiovascular Health Study / [A. Alonso, P. Jensen, F. Lopez et al.]. // PLoS One. – 2014. – № 9(10). – p. 20–432.
Walsh-Irwin C. Sick sinus syndrome / C. Walsh-Irwin, G. Hannibal. // AACN Adv Crit Care. – 2015. – № 26(4). – p. 80–376.
Belyalov F.I. Heart arrhythmia / F.I. Belyalov. – Irkutsk: RIO IGMAPO, 2014. – 352 p. – (6).
Rusk K. K. Sinus node dysfunction: recognition and treatment. / K. Rusk K., K. Scordo. // Nurse Pract. – 2012. – № 37(12). – p. 12–20.
Right versus left atrial pacing in patients with sick sinus syndrome and paroxysmal atrial fibrillation (Riverleft study): study protocol for randomized controlled trial / [T. Ramdjan, L. van der Does, P. Knops et al.]. // Trials. – 2014. – № 15. – p. 445.
Effect of pacing mode and pacing site on torsional and strain parameters and on coronary flow / [E. Papadopoulou, A. Kaladaridou, J. Mattheou et al.]. // J Am Soc Echocardiogr. – 2015. – № 28(3). – p. 54–347.
Clinical efficacy of constant cardiac pacing in patients with sick sinus syndrome / А. B.Ardashev, А. О. Dgangagava, V. M. Klushev, V. N. Ardashev. // Vestbik aritmologii. – 2005. – № 41. – p. 12–16.
A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome / [J. Nielsen, P. Thomsen, S. Højberg et al.]. // Eur Heart J. – 2011. – № 32(6). – p. 96–686.
Does atrial pacing lead to atrial fibrillation in patients with sick sinus syndrome? Insights from the DANPACE trial. / [S. Hjortshøj, S. Riahi, J. Nielsen et al.]. // Europace. – 2014. – № 16(2). – p. 5–241.
Health economic evaluation of single-lead atrial pacing vs. dual-chamber pacing in sick sinus syndrome / [L. Oddershede, S. Riahi, J. Nielsen et al]. // Europace. – 2014. – № 16. – p. 72–866.
Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation. / [S. Edwards, C. Karner, N. Trevor et al.]. // Health Technol Assess. – 2015. – № 19. – p. 1–210.
Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction / [S. Rinfret, D. Cohen, G. Lamas et al.]. // Circulation. – 2005. – № 2. – p. 72–165.
Dynamics of indicators of ABPM in hypertensive patients after installing the pacemaker / Т. Neapolitanska, I. Davidovich, S. Skopetskaya, V. Bondar. // Cardiovascular therapy and prevention. – 2011. – № 10. – p. 218.
Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients / [S. Chen, Z. Wang, M. Kiuchi et al.]. // Clin Res Cardiol. – 2016. – № 25. – p. 10–112.
Goldberger A. L. Clinical Electrocardiography. A Simplified Approach / A. L. Goldberger, Z. D. Goldberger, A. Shvilkin. – Philadelphia, 2013. – 233 p. – (Elsevier). – (8).
Rosendorffa K. Basics of cardiology Principles and Practice / Kliva Rosendorffa., 2007. – 1060 p. – (Humana Press).
Loss-of-Function SCN5A Mutations Associated With Sinus Node Dysfunction, Atrial Arrhythmias, and Poor Pacemaker Capture. / [D. Chiang, J. Kimm, S. Valdes et all.]. // Circ Arrhythm Electrophysiol. – 2015. – № 8. – p. 12–1105.
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a Report of the American College of Cardiology / [A. Epstein, J. DiMarco, K. Ellenbogen et al.]. // American Heart Association Task Force on Practice Guidelines. Circulation. – 2008. – № 117. – p. 2820–2840.
Draft recommendations for the implantation of electrical devices in violation of rhythm and conduction disturbances of the heart. The Working Group on violations of the Association of Cardiologists of Ukraine heart rhythm / O. Sichev, A. I. Frolov, V. Zinchenko, C. W. Lizogub. // Ukrainsky kardіologіchny magazine. – 2005. – № 5. – p. 94–114.
Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study / [M. Santini, A. Castro, F. Giada et al.]. // Circ Arrhythm Electrophysiol. – 2013. – № 6(1). – p. 7–101.
How to approach the patient with supraventricular tachycardia in the EP lab: A systematic overview / [D. Steven, H. Bonnemeier, T. Deneke et al.]. // Herzschrittmacherther Elektrophysiol. – 2015. – № 26. – p. 72–167.
Goel R. Supraventricular and ventricular arrhythmias / R. Goel, K. Srivathsan, M. Mookadam. // Prim Care. – 2013. – № 40. – p. 43–71.
Guidelines for pacemaker follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing / [J. Fraser, A. Gillis, M. Irwin et al.]. // Can J Cardiol. – 2000. – № 16. – p. 76–355.
Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defi brillator against amiodarone / [S. Connolly, M. Gent, R. Roberts et al.]. // Circulation. – 2000. – № 101. – p. 302–1297
Kovalenko V.N. Guide cardiology. Part 3 / V. N. Kovalenko. – Kyiv, 2008. – 1424 p. – (K: MORION).
Impact of atrial prevention pacing on atrial fi brillation burden: Primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial / [M. Gold, S. Adler, L. Fauchier et al.]. // Heart Rhythm. – 2009. – № 6. – p. 295–301.
Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients. / [S. Chen, Z. Wang, M. Kiuchi et al.]. // Clin Res Cardiol. – 2016. – p. 30–117.
Atrial-based pacing has no benefit over ventricular pacing in preventing atrial arrhythmias in adults with congenital heart disease. / [P. Opic, S. Yap, M. Van Kranenburg et.al.]. // Europace. – 2013. – № 15(12). – p. 62–1757.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy / [B. Gersh, B. Maron, R. Bonow et al.]. // Circulation. – 2011. – № 124. – p. 2761–2796.
Guidelines for cardiac pacing and cardiac recynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Recynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association / [P. Vardas, A. Auricchio, J. Fraser et al.]. // European Heart Journal. – 2007. – № 28. – p. 2256–2295.
Małecka B. Permanent cardiac pacing in women--light and shadow / B. Małecka, A. Wysokińsk. // Przegl Lek. – 2015. – № 72(4). – p. 13–209.
Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management / [A. Baxi, C. Restrepo, D. Vargas et al.]. // Radiographics. – 2016. – № 36. – p. 54–335.
Evidence From Pacing in Obstructive Hypertrophic Cardiomyopathy. / M.Sandín, V. Climent, G. Morena, F. Marín. // Rev Esp Cardiol (Engl Ed). – 2016. – № 69. – p. 532
Cardiomyopathy induced by artificial cardiac pacing: myth or reality sustained by evidence? / [A. Ferrari, A. Borges, L. Albuquerque et al.]. // Rev Bras Cir Cardiovasc. – 2014. – № 29(3). – p. 13–402.
A retrospective analysis of the use of chronic resynchronization therapy in patients with heart failure / [L. Bokeria, OL Bokeria, TS Bazarsadaeva et al.]. // Annals arrhythmology. – 2012. – № 1. – p. 32–36.
Merriam J. Newer Indications for ICD and CRT. / J. Merriam, A. Rajendra, M. Gold. // Cardiol Clin. – 2014. – № 32(2). – p. 90–181.
Fang F. Potential role of biventricular pacing beyond advanced systolic heart failure / F. Fang, J. Sanderson, C. Yu. // Circ J. – 2013. – № 77(6). – p. 9–1364.
Expanding indications for resynchronization therapy / C.Leclercq, N. Behar, P. Mabo, P. Daubert. // Curr Cardiol Rep. – 2012. – № 14(5). – p. 6–540.
Upgrading pacemaker to cardiac resynchronization therapy: an option for patients with chronic right ventricular pacing and heart failure / [S. Sideris, E. Poulidakis, C. Aggeli et al.]. // Hellenic J Cardiol. – 2014. – № 55(1). – p. 17–23.
Edner M. Pre-implant right ventricular function might be an important predictor of the response to cardiac resynchronization therapy / M. Edner, M. Ring, P. Henriksson. // Cardiovasc Ultrasound. – 2011. – № 26. – p. 9–28.
Gender-related safety and efficacy of cardiac resynchronization therapy. / [A. Schuchert, C. Muto, T. Maounis et al.]. // Clin Cardiol. – 2013. – № 36(11). – p. 90–683.
Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis. / [W. Sun, C. Li, J. Guo et al.]. // Heart Fail. Rev. – 2016. – № 4. – p. 4–100.
Effects of Cardiac Resynchronization Therapy on Ventricular Electrical Remodeling in Patients With Heart Failure. / [J. Zhang, Q. Xing, X. Zhou et al.]. // Int Heart J. – 2015. – № 56(5). – p. 9–495.
Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial. / [A. Ghotbi, M. Sander, L. Køber et al.]. // PLoS One. – 2015. – № 10(9). – p. 23–80.
Influence of heart failure etiology on the effect of upgrading from right ventricular apical to biventricular or bifocal pacing in patients with permanent atrial fibrillation and advanced heart failure /
[B. Małecka, A. Ząbek, A. Maziarz et al.]. // Pol Arch Med Wewn. – 2012. – № 122. – p. 89–97.
Reverse left ventricular remodeling is more likely in non ischemic cardiomyopathy patients upgraded to biventricular stimulation after chronic right ventricular pacing / [M. Morales, U. Startari, G. Rossi et al.]. // Cardiovasc Ultrasound. – 2011. – № 16. – p. 41.
Upgrading to resynchronization therapy in patients with heart failure after chronic right ventricular apicalpacing / [F. Lu, D. Wu, N. Fu et al.]. // Zhonghua Yi Xue Za Zhi. – 2011. – № 91(14). – p. 9–987.
Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling / [G. Fröhlich, J. Steffel, D. Hürlimann et al.]. // Eur Heart J. – 2010. – № 31(12). – p. 85–1477.
In silico study of the haemodynamic effects induced by mechanical ventilation and biventricular pacemaker / C.De Lazzari, E. Del Prete, I. Genuini, F. Fedele. // Comput Methods Programs Biomed. – 2013. – № 110(3). – p. 27–519.
Upgrading pacemaker to cardiac resynchronization therapy: an option for patients with chronic right ventricular pacing and heart failure. / [S. Sideris, E. Poulidakis, C. Aggeli et al.]. // Hellenic J Cardiol. – 2014. – № 55(11). – p. 17–23.
Warriner D. End-stage heart failure non-pharmacological therapy: recent advances in pacemakers, pressure monitors, pumps and other devices. / D. Warriner, P. Sheridan. // Postgrad Med J. – 2014. – № 90. – p. 70–1164.
Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. / [M. Neyt, S. Stroobandt, C. Obyn et al.]. // BMJ Open. – 2011. – № 1(2). – p. 40–101.
Remote monitoring of heart failure patients using implantable cardiac pacing devices and external sensors: results of the Insight-HF study / [A. Lieback, J. Proff, K. Wessel et al.]. // Clin Res Cardiol. – 2012. – № 101(2). – p. 7–101.
Cardiac Arrhythmias and Pacing 2015: A Selection of Topical Issues. / [R. Peinado, F. Ruiz-Mateas, M. Izquierdo et all.]. // Rev Esp Cardiol (Engl Ed). – 2016. – № 69. – p. 75–167.
Parameters of cardiac pacing and effectiveness of defibrillation during implantable cardioverter-defibrillator lead implantation to right ventricle outflow tract / [A. Rydlewska, A. Engel, J. Machejek et al.]. // Pol Merkur Lekarski. – 2013. – № 35(209). – p. 8–254.
Kusumoto F. Cardiac Pacing for the Clinician / F. Kusumoto, N. Goklschlager., 2007. – 742 p. – (Springer).
Do cardiologists follow the European guidelines for cardiac pacing and resynchronization therapy? Results of the European Heart Rhythm Association survey. / [E. Sciaraffia, N. Dagres, A. Hernandez-Madrid et al.]. // Europace. – 2015. – № 17. – p. 51–148.
Spanish pacemaker registry. 10th official report of the Spanish Society of Cardiology Working Group on Cardiac Pacing (2012). / [R. Coma Samartín, F. Ruiz Mateas, M. Fidalgo Andrés et al.]. // Rev Esp Cardiol (Engl Ed). – 2013. – № 66(12). – p. 72–959.
Naqvi T. Z. The next 10 years in cardiac pacing. / T. Z. Naqvi. // Expert Rev Cardiovasc Ther. – 2013. – № 11(7). – p. 9–807.
Clinical guidelines on the use of pacemakers (EKS) / [L. Bokeria, A. S. Revishvili, O.L. Gordeev et al.]. // Herald arrhythmology. – 2009. – № 58. – p. 60–79.
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation / [R. Coma Samartín, F. Ruiz Mateas, M. Fidalgo Andrés et.al.]. // Rev Esp Cardiol (Engl Ed). – 2013. – № 66(12). – p. 72–959.
Personalized Therapy of Hypertension: the Past and the Future / [P. Manunta, M. Ferrandi, D. Cusi et al.]. // Curr Hypertens Rep. – 2016. – № 18(3). – p. 24.
2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. / [J. Shin, J. Park, K. Kim et al.]. // Clin Hypertens. – 2015. – № 15. – p. 20–175.
Maltseva M.S. Prognostic value of QTc interval duration in medical management of patients after implantation of the pacemaker and CRT devices: avtoref. dis. for the sciences. the degree of PhD. : special. 14. 01.11 «cardiology»/. – Kharkiv, 2015. – 25 p.
106. Shanina I. V. Frequency of detached cardiac drugs prescribing in patients of different classes QRS complex duration on the permanent pacing background / I. V. Shanina, D. E. Volkov. // Visnik Kharkiv’s National University named after V. N. Karazin «Medicine» – 2014. – № 27. – p. 33–37.
Shanin I. V. The duration of the QRS complex and the effectiveness of drug therapy for patients with implanted pacemakers: avtoref. dis. for the sciences. the degree of PhD. : special. 14. 01.11 «cardiology»/. – Kharkiv, 2015. – 25 p.
The New Fixed Combination of Antihypertensive Drugs in Clinical Practice / [G. Gendlin, A. Melehov, O. Andreeva et al.]. // Kardiologiia. – 2015. – № 55(6). – p. 8–105.
Pareek A. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring / A. Pareek, F. Messerli, N. Chandurkar. // J Am Coll Cardiol. – 2016. – № 67(4). – p. 89–379.
Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: / [P. Gosse, D. Sheridan, F. Zannad et al.]. // J Hypertens. – 2000. – № 18(10). – p. 75–1465.
Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. / [G. Roush, M. Ernst, J. Kostis et al.]. // J Hypertens. – 2016. – № 34(1). – p. 9–11.
Mestan M. The influence of fluid and diuretic administration on the index of atrial contribution in sequentially paced patients / M. Mestan, A. Babu, J. Kvasnicka. // Europace. – 2006. – № 8(4). – p. 8–273.
Managemant of hypertension: summary of NICE guildelines / [T. Krause, K. Lovibond, M. Caulfield et al.]. // BMJ. – 2011. – № 343. – p. 5–350.
Beta-blockers for hypertension / [C. Wiysonge, H. Bradley, J. Volmink et al.]. // Cochrane Database Syst Rev. – 2012. – № 14. – p. 4–95.
How strong is the evidence for use of beta-blockers as first line therapy for hypertension? / [H. Bradley, C. Wiyonge, V. Volmink et al.]. // J Hypertens. – 2006. – № 24. – p. 2131–2141.
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / [M. Law, J. Morris, N. Wald et al.]. // BMJ. – 2009. – № 338. – p. 12–315.
Fares H. Vasodilating versus first-generation β-blockers for cardiovascular protection / H. Fares, C. Lavie, H. Ventura. // Postgrad Med. – 2012. – № 124(2). – p. 7–15.
Machado-Alba J. Results of an intervention to reduce potentially inappropriate prescriptions of beta blockers and calcium channel blockers / J. Machado-Alba, C. Giraldo-Giraldo, A. Aguirre Novoa. // Rev Calid Asist. – 2015. – № 18. – p. 7–94.
Ogrodowczyk M. Beta-Blockers: Current State of Knowledge and Perspectives / M. Ogrodowczyk, K. Dettlaff, A. Jelinska. // Mini Rev Med Chem. – 2016. – № 16(1). – p. 40–54.
Cost-effectiveness of enhancing adherence to therapy with blood pressure-lowering drugs in the setting of primary cardiovascular prevention. / [L. Scotti, G. Baio, L. Merlino et al.]. // Value Health. – 2013. – № 16(2). – p. 24–318.
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenololcombination: the EXPLOR study / [P. Boutouyrie, A. Achouba, P. Trunet et al.]. // Hypertension. – 2010. – №55. – p. 1314–1322.
Degirmenci H. Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension / H. Degirmenci, M. Açikel, E. Bakirci. // Eur Rev Med Pharmacol Sci. – 2014. – № 18. – p. 7–630.
The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial / [P. Studinger, A. Tabák, C. Chen et al.]. // J Clin Hypertens (Greenwich). – 2013. – № 15(12). – p. 7–910.
Brabham W. The role of AV and VV optimization for CRT / W. Brabham, M. Gold. // Journal of Arrhythmia. – 2013. – № 29. – p. 153–161.
2013 ESH/ESC Guidelines for the management of arterial hypertension / [G. Mancia, R. Fagard, K. Narkiewicz et al.]. // Journal of Hypertension. – 2013. – № 23(1). – p. 1281–1357.
Kryukov I. N. Ischemic heart disease. Modern aspects of the clinic, diagnosis, treatment, prevention,/ I. N. Kryukov, E. N. Nikolaev, V. P.Polyakov. – Samara: «PKI» Commonwealth, 2010. – 651 p.
Translation of clinical trial results into practice: Temporal patterns of B-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up / [P. Patel, D. White, A. Deswal et al.]. // American Heart Journal. – 2007. – № 153. – p. 515–522.
Effect of Metoprolol Versus Carvedilol on Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) / [H. Martin, H. Anne-Christine, J. Christian et al.]. // Journal of the American College of Cardiology. – 2013. – № 61. – p. 1518–1526.
Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy / A.Voigt, A. Shalaby, E. Adelstein, S. Saba. // Clin Cardiol. – 2010. – № 33(7). – p. 1–5.
Beta-blocker therapy induces ventricular resynchronization in dilated cardiomyopathy with narrow QRS complex / [Y. Takemoto, T. Hozumi, K. Sugioka et al.]. // Journal of American College of Cardiol. – 2007. – № 49. – p. 778–783.
The use of cardiac resynchronisation therapy may allow the optimisation of beta blocker therapy / [K. Guha, Z. Khalique, N. Pareek et al.]. // European Journal of Heart Failure Supplements. – 2011. – № 10. – p. 20.
Calcium channel blockers and hypertension / [G. Tocci, A. Battistoni, J. Passerini et al.]. // Cardiovasc Pharmacol Ther. – 2015. – № 20(2). – p. 30–121.
Ogimoto A. Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections / A. Ogimoto, J. Higaki. // Clin Calcium. – 2013. – № 23(4). – p. 74–569.
Chen G. The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273, 543 participants in 31 randomized controlled trials / G. Chen, M. Yang. // PLoS One. – 2013. – № 8(3). – p. 12–132.
Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study / A.Abdelhady, S. Khader, S. Sinnuqrut, A. Albow. // Clin Drug Investig. – 2016. – № 36(5). – p. 66–357.
A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients / [Y. Yang, R. Wei, Y. Xing et al.]. // Metabolism. – 2013. – № 62(12). – p. 66–1858.
Mehlum M. Visit-to-visit blood pressure variability increases risk of stroke or cardiac events in patients given valsartan or amlodipine in the value trial / M. Mehlum, K. Liestøl, S. Julius. // J Hypertens. – 2015. – № 33. – p. 3–325.
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT / [J. Yamal, S. Oparil, B. Davis et al]. // J Am Soc Hypertens. – 2014. – № 8(11). – p. 19–808.
Pharmacodynamics of amlodipine: Hemodynamic effects and antianginal efficacy after atrial pacing / [J. Kerry, M. Hogg, S. Robert et al.]. // American Heart Journal. – 1989. – № 118. – p. 1107–1113.
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST)/ / [D. Winchester, R. Cooper-Dehoff, Y. Gong et al.]. // Clin Cardiol. – 2013. – № 36(8). – p. 7–442.
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy / [S. Denardo, Y. Gong, R. Cooper-DeHoff et al.]. // PLoS One. – 2015. – № 10(4). – p. 5–115.
Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical trial / H.Shaker, F. Jahanian, M. Fathi, M. Zare. // Ther Adv Cardiovasc Dis. – 2015. – № 9(1). – p. 4–9.
A controlled study on the effect of verapamil on atrial tachycaarrhythmias in patients with brady-tachy syndrome implanted with a DDDR pacemaker / [G. Boriani, E. Bertaglia, A. Carboni et al.]. // Int J Cardiol. – 2005. – № 104(1). – p. 6–73.
Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases / [P. Rodríguez, G. Barón-Esquivias, M. Hernández et al.]. // Cardiology and Therapy. – 2016. – p. 1–8.
Barrios V. Diltiazem in the treatment of hypertension and ischemic heart disease / V. Barrios. // Expert Rev Cardiovasc Ther. – 2011. – № 9(11). – p. 82–1375.
Agbor-Etang B. Management of Hypertension in Patients with Ischemic Heart Disease / B. Agbor-Etang, J. Setaro. // Curr Cardiol Rep. – 2015. – № 17(12). – p. 119.
Kinsara A. Resting heart rate in patients with ischemic heart disease in Saudi Arabia and Egypt / A. Kinsara, H. Najm, M. Anazi. // J Saudi Heart Assoc. – 2011. – № 23(4). – p. 32–225.
Svetlii L.I. Application retard forms of diltiazem for the treatment of patients with coronary heart disease and hypertension in an outpatient setting / L. I. Svetlii, V. G. Kukes. // Kursk scientific-practical herald «Man and his health». – 2006. – № 4. – p. 63–69.
Diltiazem as an alternative to beta-blocker in coronary artery computed tomography angiography / [C. Rochitte, G. Azevedo, A. Shiozaki et al.]. // Arq Bras Cardiol. – 2012. – № 99(2). – p. 13–706.
Clinical evaluation of losartan and diltiazem on the development of T-wave memory by right apical ventricular pacing / [P. Chiale, D. Etcheverry, J. Pastori et al.]. // Am Coll Cardiol. – 2014. – № 63(18). – p. 31–1929.
Opie L. H. Angiotensin converting enzyme inhibitors. The advance continues. 3 edition. / L. H. Opie. – New-York: Authors' Publishing House, 1999. – 276 p.
Guo W. Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses. / W. Guo, L. Li. // Int J Cardiol. – 2016. – №1. – p. 2–10.
Gueyffier F. Are we using blood pressure-lowering drugs appropriately? Perhaps now is the time for a change. / F. Gueyffier, J. Wright. // J Hum Hypertens. – 2014. – № 28. – p. 68–70
Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients with Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis. / [W. Sun, H. Zhang, J. Guo et al.]. // Medicine (Baltimore). – 2016. – № 95. – p. 25–200
Sirenko Y. N. Enalapril in cardiology and Therapeutics: performance standard and security among ACE inhibitors/Y.N. Sirenko. Medicine and pharmacy news. – 2011. – № 13. – p.376–377.
The influence of dietary peptide inhibitors of angiotensin-converting enzyme on the hypotensive effects of enalapril / [M. Watanabe, J. Kurihara, S. Suzuki et al.]. // J Pharm Health Care Sci. – 2015. – № 17. – p. 1–17.
Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis / [J. DiNicolantonio, T. Hu, C. Lavie et al.]. // Ochsner J. – 2014. – № 14. – p. 8–350.
Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal / [J. Maldonado, T. Pereira, A. Tavares et al.]. // Drugs R D. – 2014. – № 14(2). – p. 54–147
Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals / [A. Beck, M. Otto, L. D'Avila et al.]. // Atherosclerosis. – 2012. – № 222 (2). – p. 8–444.
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial / [C. Funck-Brentano, D. van Veldhuisen, L. van de Ven et al.]. // Eur J Heart Fail. – 2011. – № 13(7). – p. 72–765.
Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction / [J. Flores-Monroy, C. Ferrario, I. Valencia-Hernández et al.]. // Pharmacology. – 2014. – № 94(1-2). – p. 8–21.
Systolic and diastolic component of orthostatic hypotension and cardiovascular events in hypertensive patients: the Captopril Prevention Project / A.Fedorowski, B. Wahlstrand, T. Hedner, O. Melander. // J Hypertens. – 2014. – № 32. – p. 75–81.
Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial / [H. Arima, C. Anderson, T. Omae et.al]. // Stroke. – 2011. – № 42(8). – p. 41–2339.
Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension / [R. Hatala, D. Pella, K. Hatalová et al.]. // Clin Drug Investig. – 2012. – № 32(9). – p. 12–603.
165. Dolzhenko M. N. ACE inhibitors in treatment and prevention of cardiovascular Pathology: potential ramiprila/M. N. Dolzhenko, I. N. Volgina // Consilium medicum Ukraine. – 2009. – № 2. – p. 12–15.
Side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: are we facing a new syndrome / [A. Montoro de Francisco, A. García-Luque, M. Fernández et al.]. // Am J Cardiol. – 2012. – № 110(10). – p. 3–1552
The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease / [J. Brugts, H. Arima, W. Remme et al.]. // Int J Cardiol. – 2014. – № 176(3). – p. 23–718.
Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy / [J. Penn, I. Goldenberg, S. McNitt et al.]. // J Card Fail. – 2015. – № 21(7). – p. 7–541.
Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study / [Y. Ah, J. Lee, Y. Choi et al.]. // Clin Exp Hypertens. – 2016. – № 30. – p. 1–6.
Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors / [F. Hsiao, Y. Tung, S. Chou et al.]. // Medicine (Baltimore). – 2015. – № 94(51). – p. 9–80.
Makkink J. Angiotensin converting enzyme inhibitors v. angiotensin receptor blockers in the management of hypertension: a funder's perspective / J. Makkink, O. Greeff. // S Afr Med J. – 2014. – № 104(4). – p. 4–292.
Sabbah Z. Angiotensin receptor blockers - advantages of the new sartans / Z. Sabbah, A. Mansoor, U. Kaul. // J Assoc Physicians India. – 2013. – № 61(7). – p. 70–464.
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke / [K. Kikuchi, S. Tancharoen, T. Ito et al.]. // Int J Mol Sci. – 2013. – № 14(9). – p. 924–1889.
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study / [A. Greve, M. Olsen, J. Bella et al.]. // Am J Hypertens. – 2012. – № 25(9). – p. 23–1017.
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study / [A. Ruwald, B. Westergaard, T. Sehestedt et al.]. // J Hypertens. – 2012. – № 30(6). – p. 9–252.
The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS study) / [C. Farsang, G. Abraham, P. Kovacs et al.]. // Hypertension and Neurology. – 2009. – № 2. – p. 81–88.
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data. / [L. Yu, J. Zhu, H. Tan et al.]. // Chin Med J (Engl). – 2011. – № 124(12). – p. 8–1763.
Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis / [L. Mantziari, K. Guha, Z. Khalique et al.]. // Am J Cardiol. – 2012. – № 109(11). – p. 25–1619.
Вісник Харківського національного університету імені В. Н. Каразіна, серія Медицина має такі умови авторського права:
1. Автори зберігають авторські права та надають журналу право на першу публікацію разом із роботою, яка одночасно ліцензується згідно з ліцензією Creative Commons Attribution License, яка дозволяє іншим ділитися роботою з визнанням авторства роботи та першої публікації в цьому журналі.
2. Автори можуть укладати окремі додаткові договірні угоди щодо неексклюзивного розповсюдження опублікованої журналом версії роботи з підтвердженням її початкової публікації в цьому журналі.
3. Авторам дозволяється та заохочується публікувати свої роботи в Інтернеті до та під час процесу подання, оскільки це може призвести до продуктивного обміну, а також до раннього та більшого цитування опублікованої роботи.
